Abstract
Introduction

52
Understanding drug mechanism-of-action and evaluating in cellular activity is 53 challenging (Santos et al, 2017) and widespread target promiscuity contributes to low success 54 rates during drug development (Klaeger et al, 2017) . For target-based drug development, a 55 detailed understanding of drug mechanism-of-action provides information about specificity 56 and undesirable off-target activity which could lead to toxicity and reduced therapeutic window 57 (Lin et al, 2019) . Moreover, molecular biomarkers can be used to monitor drug activity and to 58 identify contexts in which drugs are more effective as the basis for patient stratification during 59 clinical development. 60
61
The cellular activity of a drug is influenced by multiple factors including the selectivity 62 and affinity of the compound to its target(s) and the penetrance of target engagement on 63 cellular phenotypes. An array of biochemical, biophysical, computational and cellular assays 64 are currently used to investigate drug mechanism-of-action (Schenone et al, 2013) . and specifically in breast cancer cell lines. Furthermore, we defined robust pharmacogenomic 96 associations, represented by genetic biomarkers independently supported by drug response 97 and gene fitness measurements. These identify genetic contexts associated with drug-98 pathway dependency and provide a more refined set of biomarkers. Taken together, we 99 present here an approach to leverage pharmacological and CRISPR screening data to inform 100 on drug in cellular mechanism-of-action to guide drug development. 101
Results
102
Cancer cell line drug sensitivity and gene fitness effects 103 We analysed datasets from a highly-annotated collection of 484 histologically diverse 104 human cancer cell lines (Supplementary Table 1 Gene knockout fitness effects correspond with drug targets 135 We began by investigating the extent to which drug sensitivity corresponded to 136 CRISPR knock-out of drug targets. We systematically searched for associations between drug 137 sensitivity and gene fitness effects across the 484 cell lines (Figure 1a) . We expect this to 138 capture a variety of relationships ranging from direct drug-target interactions to more complex 139 associations arising from interactions with regulators of the drug target(s). We tested a total of 140 7,988,640 single-feature gene-drug associations using linear mixed regression models. 141
Potential confounding effects such as growth rate, culture conditions, data source and sample 142 structure were considered in the models. We identified 865 significant associations (FDR 143 adjusted p-value < 10%, Supplementary Additionally, the weighted network shows pathway members that have strongly correlated 215 fitness profiles, which are likely functionally related (Pan et al, 2018) . For EGFR inhibitors 216 these included tyrosine receptor kinases NTRK3 and MET, and the protein phosphatase 217 PTPN11 (Wang et al, 2017; Pan et al, 2018) (Figure 2d ). Drug-target tailored networks can be 218 used to understand drug mechanism-of-action, and have the potential to identify resistance 219 mechanisms and propose alternative targets in the network. 220 221 Despite our finding that we can illuminate drug functional networks, 46.6% (n=167) of 222 the tested drugs had no significant drug-gene associations. This could in part be explained by 223 lower variability in CRISPR fold change measurements for the target of these drugs (Figure  224 2e). For example, where genetic knockout induces strong uniform loss-of-fitness effects in 225 contrast to incomplete target inhibition by a drug (Supplementary Figure 3d) . Additionally, 226 inhibition of a protein is intrinsically different than a knockout, as observed for PARP inhibitors 227 whose activity is mediated through formation of cytotoxic PARP-DNA complexes, whereas as 228 PARP knockout has little or no effect on cells (Gill et 
251
Cancer drugs mechanism-of-action 252 Next, we set out to investigate in detail some of the strongest drug sensitivity and gene 253 fitness associations (Supplementary Table 5 observed, supporting the known genetic association that IGFR1 is a furin substrate, and 261 increased levels of furin are associated with increased levels of processed IGFR1 and worse 262 prognosis in several cancers (Thomas, 2002) . 263
264
Protein kinase inhibitors are an important class of cancer drugs (Santos et al, 2017) . 265
Because of the conserved structural features of the commonly targeted kinase domain, the 266 clinical development of kinase inhibitors is hampered by poor selectivity, which consequently 267 may lead to undesirable off-target activity (Klaeger et al, 2017) . Furthermore, some kinases 268 have multiple isoforms with non-redundant roles in tissues, as exemplified by the clinical 269 development of PI3K inhibitors, and this has led to the development of isoform-selective 270 inhibitors to reduce toxicity and increase the therapeutic window (Thorpe et al, 2015) . This revealed a previously unappreciated interaction between MARCH5 and MCL1 inhibitors, 418 with potential utility to derive predictive models of MCL1 inhibitor response across multiple 419 cancer types, and particularly in solid tumours such as breast carcinomas. Robust 420 pharmacogenomic biomarkers leveraged both datasets to provide refined biomarkers that are 421 correlated with both drug response and biological networks. Interestingly, the networks we 422 have defined can provide alternative targets that are functionally related with the drug target 423 and mediate similar effects on cell fitness, potentially providing strategies for combination 424 therapies to limit therapy resistance. 425 426 Pre-clinical biomarker development is an important step in drug discovery and is 427 associated with increased success rates during clinical development (Nelson et al, 2015) . 428 Traditionally this has been performed by building predictive models of drug response using 429 mutation, copy number and gene expression (Iorio et We anticipate this approach to be useful for many compounds, and could become a routine 451 step during drug development. In particular, it is likely to have utility during the hit-to-lead 452 optimisation stage of drug development to select lead chemical series and compounds with 453 optimal potency and selectivity. The utility of this approach is likely to expand as the availability 454 of CRISPR knock-out screening data, and other datasets such as CRISPR activation and 455 inhibition, increases across ever larger collections of highly-annotated cancer cell models. In 456 conclusion, this study illustrates a new approach for investigating in cellular drug mechanism-457 of-action that can be applied to multiple critical aspects of drug development. 458 We tested all the single-feature pairwise associations between the 480 compounds 558 and the 16,643 genes, making a total of 7,988,640 tested associations. P-value adjustment 559 for multiple testing was performed per drug using the Benjamini-Hochberg False Discovery 560 Rate (FDR). Contrary to performing the adjustment across all tests, per drug correction has 561 the following benefits: (i) associations assembled from the different screening platforms 562 (GDSC1 and GDSC2) are kept separate hence not biasing for measurement type; and (ii) 563 drugs with stronger responses across larger subsets of cancer cell lines, for example Nutlin -564 3a response across TP53 wild-type cell lines, display stronger associations than most drugs, 565 thus correcting across all drugs would retain more associations from these drugs at a specific 566 error rate, i.e. 10%, compared to the rest. 567 Tables 7 and 8) . 590
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591
L2-regularised linear regression models to predict MCL1 inhibitors drug response were 592 trained using gene fitness, gene expression measurements or both of canonical regulators of 593 MCL1, namely MARCH5, MCL1, BCL2, BCL2L1, BCL2L11, PMAIP1, BAX, BAK1, BBC3, BID,  594 BIK, BAD. For the 9 MCL1 inhibitors considered in this study predictive models of drug 595 response measurements were trained using Ridge regressions with an internal cross-596 validation optimisation of the regularization parameter, implemented in Sklearn with RidgeCV 597 class (Pedregosa et al, 2011) . Additionally, drug response measurements are split randomly 598 1,000 times, where 70% of the measurements are for training the model and 30% are left out 599 as a test set. Model's performance is quantified using the R2 metric on the test set, comparing 600 the predicted versus the observed drug response measurements. 601 IGF1R  CNPY2  FURIN  IRS2  KBTBD2   CPD  PIK3CB  STT3A  HSP90B1   IRS1  MCL1  MARCH5  PIK3CA  RICTOR  MAPKAP1   MCL1  MARCH5   MCL1  MARCH5  MATN4  MCL1  MARCH5   MCL1  MARCH5   BRAF  MAPK1  PEA15  NFATC2  SYNGR2  GTPBP4  TIPRL  FGFR2  EXT2  ATOH1  FGFR1  EXT1  GLCE  EXTL3  RNH1  AHCYL1  HIGD2A   MET  GAB1  OCM  CAV1  FCHO2 Taselisib  Venetoclax  AZD8835  AZD8186  AZD5582  SGX-523   MCL1  MARCH5  EGFR  SHC1  UGCG  GRB2  TP63  SSR2  ATPIF1  STT3A  EGFR  SHC1  GRB2  GAB1  ITGA3  EGFR  SHC1  GAB1  GRB2  ZNF117  KLF5  PIK3CA  RICTOR  MAPKAP1   PNKD  BCL2  TMEM189  TMEM161B   UROS  IRF8  PIK3CA  MAPKAP1  RICTOR  ERBB3  PIK3CB  RICTOR  MLST8  MAPKAP1   PDCL  MAP3K7  TRAF2  RNF31  ATG9A  MET Gefitinib  Savolitinib  BMS-754807   FGFR2  ATOH1  EXT2  AHCYL1  EXT1  EXTL3  CTSH  RNH1  FGFR2  EXT2  FGFR1  ATOH1  EXTL3  EXT1  B4GALT7   HIPK3  SLC35B2   RNH1  MET  GAB1  CAV1  RICTOR  AKT1  MAPKAP1   MLST8  AKT2  PIK3CA  ERBB2  EGFR  SHC1  MIEN1  CDC37  RECK  ERBB3  GRB2  PIK3CA  RICTOR  MAPKAP1   AKT1  FGFR2  ATOH1  EXT2  EGFR  SHC1  TP63  GRB2  GAB1  ITGA3  GAB1  MET  CAV1  TSHZ1  PTPN11  IGF1R  FURIN  IRS2  CNPY2  CPD (-)   EGFR  SHC1  ERBB2  GAB1  GRB2  MAP3K7  TRAF2  RNF31  BIRC2  SPDEF  PDE10A  ERBB2  EGFR  SHC1  MIEN1  CDC37  GRB2  MARCH5   MCL1  ERBB2  EGFR  SHC1  ITGA3  GRB2  PHLDA3  MIEN1  GAB1  CBLC  TP63  RICTOR  MAPKAP1   AKT1  MLST8  HIST2H2BF  HSP90B1  IGF1R  CNPY2  FURIN  IRS2  ATOH1  SLC39A1  TUBD1  BRAF  ELAVL1   LIF  MITF  TIPRL  ERBB2  SHC1  MIEN1  EGFR  GRB2  ERBB3  PGAP3  HAP1  MDM2  TP53  MDM4  PPM1D  USP28  UBE3B  TP53BP1  LTA4H Ibrutinib  EGFR_8897  Osimertinib  MCT1_6447  PF-06747775  ASLAN002  Tepotinib   BRAF  NFATC2  EGFR  ERBB2  SHC1  GRB2  RICTOR  MAPKAP1   AKT1  C8B  MLST8  STX4  ERBB2  SHC1  EGFR  GRB2  ERBB3  HAP1  STXBP3  ERBB2  SHC1  EGFR  ERBB3  GRB2  MIEN1  ERCC8  ERBB2  EGFR  GRB2  SHC1  GAB1  SLC16A1  CARD9  ERBB2  EGFR  SHC1  GRB2  GAB1  CDC37  MIEN1  TIPIN  HAP1  MET  GAB1  MET 
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